|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Contrast-enhanced ultrasound of histologically proven hepatic epithelioid hemangioendothelioma显示文摘AIM: To analyze contrast-enhanced ultrasound(CEUS) features of histologically proven hepatic epithelioid hemangioendothelioma(HEHE) in comparison to other multilocular benign focal liver lesions(FLL).METHODS: Twenty-five patients with histologically proven HEHE and 45 patients with histologically proven multilocular benign FLL were retrospectively reviewed. Four radiologists assessed the CEUS enhancement pattern in consensus.RESULTS: HEHE manifested as a single(n = 3) or multinodular(n = 22) FLL. On CEUS, HEHE showed rim-like(18/25, 72%) or heterogeneous hyperenhancement(7/25, 28%) in the arterial phase and hypoenhancement(25/25, 100%) in the portal venous and late phases(PVLP), a sign of malignancy. Eighteen patients showed central unenhanced areas(18/25, 72%); in seven patients(7/25, 28%), more lesions were detected in the PVLP. In contrast, all patients with hemangioma and focal nodular hyperplasia showed hyperenhancement as the most distinctive feature(P < 0.01).CONCLUSION: CEUS allows for characterization of unequivocal FLL. By analyzing the hypoenhancement in the PVLP, CEUS can determine the malignant nature of HEHE. | Yi Dong Wen-Ping Wang Vito Cantisani Mirko D'Onofrio Andre Ignee Lorenzo Mulazzani Adrian Saftoiu Zeno Sparchez Ioan Sporea Christoph F Dietrich | 2016 | World Journal of Gastroenterology2016，22，19： | 21 |
| 2 | Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma显示文摘AIM: To better define the efficacy and the safety of intra-arterial infusion performed with or without hemofiltration for recurrent limb melanoma. METHODS: Patients with the following characteristics were included in the study: recurrent limb melanoma not indicated for surgical resection, measurable disease in the extremity, > 18 years, performances status(Eastern Cooperative Oncology Group) was 0-1 and life expectancy of at least 6 mo. Twenty nine consecutive patients were enrolled in the study. Patients underwent fluoroscopic placement of angiographic arterial and venous catheters to infuse the drug in the artery [isolated limb infusion(ILI)], and to stop the out flow(venous). Melphalan was rapidly infused into the isolated limb via the arterial catheter after the inflation of venous balloon catheter. Then the circulation of the limb was completely blocked with a pneumatic cuff at the root of the limb. Haemofiltration(HF) was available only in the main center, and was performed with an extracorporeal perfusion system, in order to reduce high systemic toxic peaks of drug.RESULTS: Thirty seven ILI were done in 29 cases(31 ILI-HF and 6 ILI) between 2001 and 2014 at Ancona and Pesaro Hospitals, Italy. Clinical outcomes were monitored 30 d after treatment. Eleven patients(38%) received infusion of melphalan alone, 7(24%) melphalan associated to mitomicin C and 7(24%) melphalan associated to cisplatin, the remaining 4 were treated with cisplatin, melphalan and epirubicin or cisplatin and mitomicin C. The overall response rate was 66%, in particular, 3 patients(10%) were complete responders and 16(56%) were partial responders; whereas 7 patients(24%) had stable disease, and 3(10%) showed progressive disease. Limb toxicity was assessed adopting Wieberdink scale, with evidence of 90% of low grade(I and II) toxicity.CONCLUSION: ILI-HF and ILI are effective and safe treatments for recurrent non-resectable limb melanoma. They present evidence of favorable clinical benefit and is effective in delaying progression. | Sara Cecchini Donatella Sarti Stefano Ricci Ludovico Delle Vergini Manuela Sallei Stefano Serresi Giuseppe Ricotti Luca Mulazzani Fabrizia Lattanzio Giammaria Fiorentini | 2015 | World Journal of Clinical Oncology2015，6，4： | 2 |
| 3 | Dark Clouds on the Horizon: Using Cloud Storage as Attack Vector and Online Slack Space显示文摘 | MULAZZANI M SCttRITI'WIESER S LEITHNER M | 2011 | 20th USENIX Security Symposium2011，，： | 1 |
| 4 | Friend-in-the-middle attacks,Exploiting Social Networking Sites foe Spam显示文摘 | Huber M Mulazzani M Kitzler G | | 0，，03： | 1 |
| 5 | Compact n-Manifolds via(n+l)-Colored Graphs:a New Approach显示文摘We introduce a representation via(n+l)-colored graphs of compact n-manifolds with(possibly empty)boundary,which appears to be very convenient for computer aided study and tabulation.Our construction is a generalization to arbitrary dimension of the one recently given by Cristofori and Mulazzani in dimension three,and it is dual to the one given by Pezzana in the 1970s.In this context we establish some results concerning the topology of the represented manifolds:suspensions,fundamental groups,connected sums and moves between graphs representing the same manifold.Classification results of compact orientable 4-manifolds representable by graphs up to six vertices are obtained,together with some properties of the G-degree of 5-colored graphs relating this approach to tensor models theory. | Luigi Grasselli Michele Mulazzani | 2020 | Algebra Colloquium2020，27，1： | 0 |
| 6 | Locoregional therapy and systemic cetuximab to treat colorectal liver metastases显示文摘AIM: To investigate efficacy and safety of second-line treatment with irinotecan-loaded drug-eluting beads(DEBIRI) and cetuximab(DEBIRITUX) of unresectable colorectal liver metastases.METHODS: Patients with the following characteristics were included in the study: unresectable hepatic metastases from colorectal carcinoma(CRC-LM), progression after first line chemotherapy(any type of chemotherapeutic drug and combination was allowed), second line treatment(mandatory), which included for each patient(unregarding the KRas status) two cycles of DEBIRI(using 100-300 μm beads loaded with irinotecan at a total dose 200 mg) followed by 12 cycles of cetuximab that was administered weekly at a first dose of 400 mg/m2 and then 250 mg/m2; good performance status(0-2) and liver functionality(alanine aminotransferase and gamma-glutamyl transferase not exceeding three times the upper limit of normal, total bilirubin not exceeding 2.5 mg/m L). Data were collected retrospectively and included: tumor response(evaluated monthly for 6 mo then every 3 mo), overall response rate(ORR), KRas status, type and intensity of adverse events(G according to the Common Terminology Criteria for Adverse Events v3.0, CTCAE), overall survival(OS) and progression free survival(PFS).RESULTS: Forty consecutive cases of CRC hepatic metastases were included in the study. Median duration of DEBIRITUX was 4.4 mo(range, 4.0-6.5). Sixteen patients(40%) received the planned 2 cycles of DEBIRI and an average of 10 cetuximab cycles. ORR of the whole sample was 50%, in particular 4 patients were complete responders(10%) and 16(40%) partial responders. The most observed side effects(G2) were: post-embolization syndrome(30%), diarrhea(25%), skin rushes(38%) and asthenia(35%). The retrospective evaluation of KRas status(24 wild type, 16 mutated) showed that the group of patients with wild type KRas had ORR significantly higher than mutant KRas. Median follow-up was 29 mo(8-48 range); median PFS was 9.8 mo and OS was 20.4 mo. Future randomized trials are required in this setting to establish a role for DEBIRITUX compared with systemic chemotherapy.CONCLUSION: DEBIRITUX seems to be efficacious after first line chemotherapy for the treatment of unresectable CRC-LM. | Giammaria Fiorentini Camillo Aliberti Donatella Sarti Paolo Coschiera Massimo Tilli Luca Mulazzani Paolo Giordani Francesco Graziano Alfonso Marqués Gonzalez Raul García Marcos Fernando Gómez Mugnoz Maurizio Cantore Stefano Ricci Vincenzo Catalano Andrea Mambrini | 2015 | World Journal of Gastrointestinal Oncology2015，7，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员